Biotech Values

[mcbio]

The best Alopecia Areata trial result was obtained with oral Ruxolitinib. ACRS appears to be far behind INCY which is running a P2 topical ruxolitinib and CNCE which has a P2 with a oral deuterated ruxolitinib. www.investorvillage.com/smbd.asp?mb=18114&mn=596&pt=msg&mid=16391346

Thanks to you and pgs for the posts. One other point is that ACRS has talked up the patents they own in this space (acquired from Columbia and RIGL in part I believe). I wonder if INCY has patents specific to use of JAKs for alopecia and related disorders or if ACRS could stand to benefit on this front (even if actually behind in the clinic).